Veterans Affairs Secretary Doug Collins wants to find out whether psychedelic drugs can successfully treat veterans with PTSD or traumatic brain injuries, he told a House Appropriations subcommittee hearing on Thursday. Politico’s Natalie Fertig reports. Collins pointed out that there are 11 trials underway at the VA into use of psychedelics like psilocybin and MDMA. Publicly traded companies in the space include Atai Life Sciences (ATAI), Enveric Biosciences (ENVB), Incannex (IXHL), Relmada Therapeutics (RLMD), Cybin (CYBN), Bright Minds (DRUG), and NRx Pharmaceuticals (NRXP).
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- Psychedelic: Atai, Enveric, Incannex and Relmada report quarterly results
- Atai Life Sciences: Progress in Psychedelic Mental Health Treatments
- Atai Life Sciences reports Q1 EPS (15c), consensus (18c)
- Atai Life Sciences sees cash runway into 2027
- Atai Life Sciences announces first patient dosed in Phase 2 study of EMP-01